Brain Scientific is a top growth pick for
2021 and beyond
Stay updated on company news and announcements
These patients include people of all ages: TBls and head traumas arriving in ICUs and EDs as well as suffers of epilepsy, Alzheimer’s, dementia, strokes, seizures, sleeping disorders, migraines, and encephalitis.
EEG tests are vastly undersupplied throughout the US, and globally it’s worse. This is due to a lack of readily available hardware, which is already operated on dated technology and equipment, The shortage is exacerbated by a lack of trained and qualified medical staff to administer and then interpret the results of the EEG tests.
Concussion occur each year ln the USA.
Migraine suffers in the USA.
Suffers of depression
– Most common In those oged 18-25
In the USA someone hos o stroke every 40 seconds.
ICU and ER patients
Epilepsy and Alzheimer’s sufferers
Migraine, Sleep Disorder, Encephalitis, and Stroke, patients.
1 in 6 Americans are currently affected by brain disease
A globally aging population is increasing the shortage of specialists to conduct and interprete EEGs.
Less than 1% of US hospitals are level 4 epilepsy center, with 24/7 EEG coverage
Only 30% of US hospitals have the equipment and on-hand professionals to perform an EEG
Sources: www.grandviewresearch.com
Sources: www.worldometers.info/coronavirus/worldwide-graphs/
There is no detailed knowledge of what these neurological conditions may be or may mean for the afflicted. EEGs are going to be instrumental in diagnosing and organizing treatment for those afflicted.
Brain Scientific’s revolutionary technological advancements in the world of EEGs are going to be key players in the rapid advancement of neurological discoveries and treatment insights in this area. This represents a huge opportunity for growth the company valuation.
In the US a rapidly aging population Is creating a shortage of neurologists, and 20 states have fewer than 10 neurologists per 10,000 patients. These areas are called ‘neurology deserts’. Worldwide, there are neurology deserts much larger than those in the US, which leaves a large percentage of world’s population untreated because their neurological afflictions go undiagnosed.
Brain Scientific has commenced development of its market disrupting proposed Brain E-Tattoo device for the brain diagnostics market, utilizing revolutionary, Nobel Prize winning material graphene, which is expected to feature minimally invasive, subcutaneous graphene electrode implants paired with a micro EEG. The proposed Brain E-Tattoo device is expected to allow for long-term monitoring capabilities and uninterrupted data collection from patients with neurological conditions such as epilepsy, Alzheimer’s disease, stroke, and other brain disorders.
Via a graphene based electrode system connected to a micro EEG that is clipped behind the ear, signals are collected by the sensors and wirelessly and securely stored in the cloud, where Al performs continuous analysis.
Both of these technologies are market disruptors. Integration with Al and machine learning will enable faster, more accurate diagnostics, improved predictability of events such as strokes and seizures before they actually happen, and enable a better standard of care.
Brain Scientific is a great opportunity for seasoned industry veterans as well as first time investors.
This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For risks relating to this offering, see the Subscription Agreement for this offering.
“Our current EEG device is about the size of a stamp. By shrinking the technology, the system allows for continuous measurement during a person’s normal activities, while providing a non-intrusive way to monitor various disorders,”
Dr. Baruch Goldstein has over two decades of experience in neuro-net informatics, brain image recognition and processing, artificial intelligence and management of robotic systems. Goldstein’s growth-focused leadership style has helped him raise over $750 million in venture capital to develop innovative companies and startups in diverse industries.
Dr. Nickolay V. Kukekov is a founding partner at HRA Capital and a Senior Managing Director at Paulson Investment Company. He previously worked as a senior healthcare investment banker at a number of healthcare boutique firms that include Rodman & Renshaw, Paramount Capital, Summer Street Research Partners, Merriman Capital, etc.
Through his illustrious career, Kukekov has attained a Bachelor’s degree in Molecular, Cellular and Developmental Biology from the University of Colorado at Boulder and a Ph.D. in Neuroscience from Columbia University, College of Physicians and Surgeons in New York. Along the way, he has picked up several prestigious research scholarship awards and been featured in various peer-review publications.
Amy Griffith is a seasoned professional and an innovative sales expert with years of experience in the medical and healthcare industries. She leads the development of strategic and tactical initiatives and new sales strategies for Brain Scientific. Previously, Griffith has held senior positions at technology companies and has worked with numerous start-ups on creating and implementing strategic sales programs. At Glaxosmithkline, she promoted a product portfolio to over 400 psychiatrists, neurologists, internists, OB/GYN, and family practice physicians.
Irina Nazarova is a media and marketing professional with an extensive journalism background, specializing in Content Strategy, Digital Marketing, and Public Relations.
She previously held a CEO role at 7+7 Media, Inc. In 2010-2016, she was a publisher of DOM-2 Magazine and Moscow: Instructions for Use Newspaper. Nazarova graduated from The New School (Media Management) and Moscow State University (Journalism).
Brian Scientific (OTC:BRSF) is a top stock pick for 2021, expecting exceptional growth in the very near future. Two patented, FDA approved devices are going to lead the expansion of EEGs and the availability of neurological care through the new, high growth market of teleneurology. This is an opportunity not to be missed! Brain Scientific will soon be the lead player in the neurology tech space with tt1eir revolutionaty, 3rd party compatible equipment which will soon be present In every market in the USA.
“How many millionaires do you know who have become wealthy by investing in savings accounts? I rest my case.” — Robert G. Allen
Powered by A.I., Brain E-Tattoo Technology is Expected to Provide Continuous Monitoring for Uninterrupted Data Collection in Patients with Epilepsy, Alzheimer’s, Stroke, and More.
Widening Its Investor Network Will Allow Brain Scientific to Continue Its Work in Creating Advanced Technology Devices and Software for the Neurology Market.
Our main mission as an independent research group is to raise awareness of investment opportunities that can help us bring new solutions to the industry.
Forward-Looking Statement Disclaimer: This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "Risk Factors" in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC's website, http://www.sec.gov.
Safe Harbor: Statements in this presentation that are not descriptions of historical facts are forward-looking statements relating to future events, and as such all forward-looking statements are made pursuant to the Securities Litigation Reform Act of 1995. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance, and developments, as well as other statements relating to future operations and results. Any statements in this presentation that are not statements of historical fact may be considered to be forward-looking statements. Words such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate,” “intends,” “goal,” “objective,” “seek,” “attempt,” or variations of these or similar words, identify forward-looking statements.